Inventor · disambiguated record
Hans Dietrich Menssen
Also filed as: MENSSEN HANS · MENSSEN HANS DIETRICH
4 granted patents·13 pending applications·37 citations·filing 1997–2023
71Inventor score
Top patents by PatentIndex Score
17 records- 0181US7851599B2Combination of an anti-ED—B fibronectin domain antibody—IL-2 fusion protein and gemcitabinePHILOGEN SPA·Filed 2007·Granted Dec 14, 2010·10 cites·20 claims
- 0263US8796426B2Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpartNERI DARIO·Filed 2008·Granted Aug 5, 2014·0 cites·18 claims
- 0359US9289470B2Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpartPHILOGEN SPA·Filed 2014·Granted Mar 22, 2016·0 cites·29 claims
- 0459US2010310454A1Combination of an anti-edb fibronectin antibody-il-2 fusion protein, and a molecule binding to b cells, b cell progenitors and /or their cancerous counterpartNERI DARIO·Filed 2008·Application pending·0 cites
- 0557US6521460B1Method of carrying out blood testsRHEIN BIOTECH PROZ & PROD GMBH·Filed 1997·Granted Feb 18, 2003·27 cites·21 claims
- 0655US2024190971A1USE OF an anti-P-selectin antibodyMIGLIACCIO ANNA RITA FRANCO·Filed 2023·Application pending·0 cites
- 0755US2009117073A1Use of a fusion protein targeting the ed-b fibronectin domain for treatment of atherosclerosisMENRAD ANDREAS·Filed 2007·Application pending·0 cites
- 0851US2024301054A1Tim-3 inhibitors and uses thereofNOVARTIS AG·Filed 2020·Application pending·0 cites
- 0948US2023338374A1Mdm2 inhibitors for use in the treatment or prevention of hematologic neoplasm relapse after hematopoietic cell transplantationNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1048US2022306737A1Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosisNOVARTIS AG·Filed 2020·Application pending·0 cites
- 1146US2011123444A1Use of radioactively labelled molecule specifically binding to ED-B fibronection in a method of treatment of Hodgkin lymphomaBAYER SCHERING PHARMA AG·Filed 2009·Application pending·0 cites
- 1244US2021002374A1USE OF an anti-P-selectin antibodyMIGLIACCIO ANNA RITA FRANCO·Filed 2019·Application pending·0 cites
- 1344US2023372334A1Use of an erk inhibitor for the treatment of myelofibrosisNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1444US2024000777A1Use of an erk inhibitor for the treatment of myelofibrosisNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1544US2022331318A1Use of an mdm2 inhibitor for the treatment of myelofibrosisNOVARTIS AG·Filed 2020·Application pending·0 cites
- 1642US2024301053A1Combination therapies with venetoclax and tim-3 inhibitorsNOVARTIS AG·Filed 2020·Application pending·0 cites
- 1742US2023058489A1Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemiaNOVARTIS AG·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Hans Dietrich Menssen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →